Dedicated to Brain Health & Inflammation

Our Therapeutic Focus

Remi

Therapeutics

Committed to transforming brain health with innovative medicines for complex inflammatory & neurological conditions

Remi Therapeutics is a pioneering biotechnology company with a robust pipeline focused on transforming the impact and outcomes of the most devastating conditions.

Our deep understanding of neuronal function and physiology has enabled us to identify and acquire assets that will improve the standard of care for a variety of neurological & inflammatory conditions. We continue to take bold, calculated risks to advance our pipeline and ensure that all our investors realize asymmetric returns.

Why We Exist

Disease Areas

Autism spectrum disorder (ASD) is a developmental condition marked by persistent challenges in social interaction and the presence of restricted, repetitive behaviors, interests, or activities. These characteristics can lead to significant difficulties in communication and participation in everyday life. Essentially, ASD can affect how individuals connect with others and navigate the world around them, often making routine interactions and tasks a unique challenge.

Approximately 1 in 36 children in the US have ASD, translating to about 2.8% of children. Among adults, an estimated 2.2% are living with ASD

The global ASD treatment market is projected to grow significantly, reaching approximately USD 4.5 billion by 2028, driven by increasing prevalence and rising awareness

Specific Diseases:

Autism
Asperger Syndrome
Childhood Disintegrative Disorder
Pervasive Developmental Disorder-Not Otherwise Specified (PDD-NOS)

Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by pervasive patterns of inattention, hyperactivity, and impulsivity. These symptoms can lead to significant challenges in various aspects of daily life, including academic performance, occupational functioning, and social interactions.

Approximately 6.1 million children aged 2-17 have been diagnosed with ADHD, and about 4.4% of adults are estimated to have ADHD.

The global ADHD medication market is projected to grow, with estimates suggesting it will reach USD 25.4 billion by 2030.

Specific Diseases:

ADHD, predominantly inattentive presentation
ADHD, predominantly hyperactive-impulsive presentation
ADHD, combined presentation

Cholinergic Anti-Inflammatory Pathway (CAP) disorders involve a malfunction in the body's ability to regulate inflammation through acetylcholine, a neurotransmitter that suppresses excessive immune responses. Dysregulation of CAP can contribute to several inflammatory conditions, including rheumatoid arthritis, inflammatory bowel disease, and others. Cholinergic agonists, which enhance the activity of acetylcholine, represent a promising therapeutic strategy to manage these conditions by reducing inflammation and mitigating immune system overactivity.

The global market for cholinergic agonists in treating CAP-mediated diseases is projected to grow significantly, potentially reaching billions of dollars as research advances and the prevalence of inflammatory disorders increases.

Specific Diseases:

Rheumatoid Arthritis
Inflammatory Bowel Disease (IBD)
Sarcopenia
Other Chronic Inflammatory Disorders

Get In Touch

info@remitherapeutics.com